Share to
On January 3, 2022, the Food & Drug Administration (FDA) of United States of America granted permission to Accro Bioscience Inc. for clinical trial of its lead drug candidate AC-003. Accro Bioscience Inc. owns all intellectual property rights and global interests of AC-003.
AC-003 is a novel oral small-molecule inhibitor of receptor interacting protein kinase 1(RIPK1) and has the potential for treating idiopathic pulmonary fibrosis.
